Govt portal to keep tabs on antibiotics sales

Identity of doctors prescribing any medicine and patients' profiles must be part of the database

med
.
Veena Mani New Delhi
Last Updated : Mar 18 2017 | 12:58 AM IST
Aiming to curb arbitrary consumption of antibiotics, the health ministry and the central drugs regulator are developing an online platform, where all chemists and druggists will have to register. 

Stockists and retailers will also be required to submit data on the stock they procure. Stocks returned to the manufacturer would also be updated on the centralised platform. Drug manufacturers will have to register themselves and update sales of drugs to distributors and wholesalers, with expiry dates. 

With anti-microbial resistance on the rise, the government is working on a track-and-trace mechanism through the centralised portal, according to a health ministry notice to stakeholders, inviting comments by April 15. While the identity of doctors prescribing any medicine must be part of the database, patients’ profiles will have to be included as well in the case of high-risk drugs and narcotics. The notice also says no habit-forming drug can be exported against internet orders. 

The government had earlier introduced bar-coding on primary, secondary and tertiary packs of drugs meant to be exported. However, this mechanism was not made mandatory for domestic circulation.  

The notice suggests details of all sales have to be updated by chemists — online and offline — from time to time. This would include drugs dispensed by hospitals. The notice, reviewed by Business Standard, says, “Hospitals and other clinical establishments or other authorised persons, both in the public and the private sector, shall be required to enter details of medicines dispensed or distributed, issued or made available to patients.” 


 

In urban areas, updates have to be in real-time. In rural and remote regions, pharmacies will be allowed to upload data once every fortnight. Bejon Misra, founder, Consumer Online Foundation, says this will help assess whether slashing the prices of drugs does ensure accessibility to medicines and that nobody sells above the level fixed by the National Pharmaceutical Pricing Authority.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story